FDA Saleable Returns Verification Requirements: DSCSA Compliance Guide for Distributors

As of November 27, 2024, wholesale drug distributors must verify prescription drug products at the package level before returning them to saleable inventory under the Drug Supply Chain Security Act (DSCSA). This requirement marks the full enforcement phase of the DSCSA's enhanced drug distribution security standards, codified in 21 U.S.C. 360eee-1 and implemented through FDA guidance documents issued between 2019 and 2023.

Regulatory Context

The DSCSA, enacted in 2013 and phased in over a decade, requires an electronic, interoperable system for tracing prescription drugs distributed in the United States. The Act establishes requirements for manufacturers, repackagers, wholesale distributors, and dispensers to provide transaction information, transaction history, and transaction statements for each product transaction.

On November 27, 2023, the DSCSA's Enhanced Drug Distribution Security requirements took effect, requiring verification and tracing at the package level rather than lot level. Wholesale distributors received a one-year stabilization period for certain requirements, including saleable returns verification. That stabilization period ended November 27, 2024.

Under 21 U.S.C. 360eee-1(d)(1)(B), wholesale distributors must "not accept ownership of a product unless the previous owner prior to, or at the time of, the transaction provides the transaction history, transaction information, and a transaction statement." For returned products, this translates to package-level verification before the product re-enters inventory designated for sale.

Saleable Returns Verification Requirements

When a wholesale distributor receives a prescription drug product returned from a trading partner—whether a dispenser, another distributor, or a manufacturer—the distributor must verify the product's package identifier and transaction data before the product can be sold again.

The verification process requires:

Package Identifier Verification: The distributor must scan or otherwise capture the Serialized Numerical Identifier (SNI), National Drug Code (NDC), lot number, and expiration date from the product's 2D barcode. This is the standardized package identifier under 21 U.S.C. 360eee(12).

Transaction Information Validation: The distributor must confirm that transaction information received from the returning party matches the product package identifier. Transaction information includes the proprietary or established name of the product, strength and dosage form, container size, number of containers, lot number, transaction date, shipment date, and business name and address of both parties.

Product Verification via DSCSA Exchange: The distributor must verify the product identifier through an authorized DSCSA solution, typically via ATP (Authorized Trading Partner) verification or VRS (Verification Router Service) lookup. This step confirms the product is not counterfeit, diverted, or subject to a recall.

Documentation: The distributor must maintain records of the verification for six years, per 21 U.S.C. 360eee-1(d)(4).

Failure to complete these steps before returning the product to saleable inventory constitutes a DSCSA violation. The product must remain in quarantine or segregated status until verification is complete.

Operational Impact on Wholesale Distributors

This requirement fundamentally changes returns handling workflows. Prior to November 27, 2024, many distributors processed returns at the lot level, verifying product identity through NDC and lot number but not scanning individual package identifiers. That process is no longer sufficient.

Distributors must now implement or upgrade systems capable of:

• Scanning 2D barcodes on individual packages
• Routing verification requests to ATP databases or VRS-connected solutions
• Receiving and processing verification responses
• Blocking inventory re-entry until verification clears
• Generating and storing verification audit records

For distributors handling high volumes of returns—particularly those serving specialty pharmacies, retail chains, or reverse logistics operations—this represents a significant systems and process investment. The requirement applies to all prescription drug products subject to DSCSA, which excludes only specific categories defined in 21 U.S.C. 360eee(1): blood and blood components, radioactive drugs, imaging drugs used in research, IV solutions, medical gases (with exceptions for oxygen), homeopathic drugs marketed without FDA approval, and drugs compounded in accordance with section 503A or 503B of the FDCA.

For 3PLs performing returns processing on behalf of distributor clients, the verification obligation remains with the licensed wholesale distributor, but the 3PL must have the technical capability to execute the verification as part of the service.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. Of these entities, 1,234 hold active FDA registration—a foundational requirement for DSCSA participation. However, FDA registration alone does not indicate saleable returns verification capability. The technical systems required to scan package identifiers, route ATP verification requests, and maintain DSCSA audit records represent a higher operational bar than basic registration.

The average compliance score in the ColdChainCheck directory is 51/100, placing the majority of tracked entities in the "Fair" tier (919 entities). The score reflects verified licensing, accreditation, and regulatory signals—not DSCSA system readiness, which is not publicly disclosed through state board or FDA databases. Only 63 entities hold NABP accreditation (formerly VAWD), which requires a more rigorous compliance audit but also does not specifically validate package-level verification systems.

73 entities in the directory have at least one FDA recall, warning letter, or enforcement action on record. While these signals do not directly indicate DSCSA non-compliance, they suggest gaps in quality systems or regulatory adherence that may extend to returns handling processes.

Practical Steps for Compliance Officers

Verify your trading partners' DSCSA capabilities. If you are a manufacturer or dispenser returning products to a distributor, confirm that the distributor can receive and process serialized transaction data. Check the distributor's compliance posture using the ColdChainCheck directory. Look for FDA registration, state licensure in your jurisdiction, and NABP accreditation status.

Audit your returns workflow before the next trading partner audit. Map the process from product receipt to verification to inventory re-entry. Document how package identifiers are captured, which DSCSA solution performs ATP verification, and where verification records are stored. If you use a 3PL for returns processing, obtain written confirmation of their verification capability.

Track enforcement activity. ColdChainCheck monitors FDA warning letters and state board enforcement actions. Returns verification violations will likely appear first as "lack of transaction data" or "failure to verify product identifier" citations. Review the DSCSA compliance checklist for wholesale distributors for ongoing coverage of DSCSA enforcement trends.

Cross-reference distributor claims against independent data. If a distributor states they are "DSCSA-compliant," verify that claim against ColdChainCheck's licensure and accreditation data. A distributor without active state licenses or FDA registration cannot legally distribute prescription drugs, regardless of their DSCSA system claims.

Disclaimer: This article provides informational content based on publicly available regulatory guidance and ColdChainCheck directory data as of January 2026. It is not legal or compliance advice. Distributors should consult qualified legal counsel and verify all requirements with the FDA and relevant state boards of pharmacy.